Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China · Delayed Price · Currency is CNY 25.88
+0.83 (3.31%)
Aug 31, 2026, 3:00 PM CST
SHA:600566 Revenue
Hubei Jumpcan Pharmaceutical had revenue of 1.12B CNY in the quarter ending June 30, 2026, a decrease of -8.38%. This brings the company's revenue in the last twelve months to 5.80B, down -13.86% year-over-year. In the year 2025, Hubei Jumpcan Pharmaceutical had annual revenue of 6.22B, down -22.43%.
Revenue (ttm)
5.80B
Revenue Growth
-13.86%
P/S Ratio
3.98
Revenue / Employee
1.40M
Employees
4,137
Market Cap
23.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.22B | -1.80B | -22.43% |
| Dec 31, 2024 | 8.02B | -1.64B | -16.96% |
| Dec 31, 2023 | 9.65B | 658.17M | 7.32% |
| Dec 31, 2022 | 9.00B | 1.37B | 17.90% |
| Dec 31, 2021 | 7.63B | 1.47B | 23.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
Revenue RankingsHubei Jumpcan Pharmaceutical News
- 3 days ago - Hubei Jumpcan Pharmaceutical Quarterly report: Q2 2026 - Filings
- 4 months ago - Hubei Jumpcan Pharmaceutical Annual report: H2 2025 - Filings
- 4 months ago - Hubei Jumpcan Pharmaceutical Quarterly report: Q1 2026 - Filings
- 11 months ago - Hubei Jumpcan Pharmaceutical Quarterly report: Q3 2025 - Filings